ipharmacy

FDA Safety Alert

Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

U.S. Food and Drug Administration
October 14, 2026
ID: http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-health-issues-voluntary-nationwide-recall-argatroban-injection-due-presence-particulate-matter

FDA MedWatch Safety Alert

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terepht

Content syndicated from the official FDA MedWatch Safety Alerts and Adverse Event Reporting Program.

View Official Announcement on FDA.gov